+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hemophilia AAV Gene Therapy Market - Global Forecast 2026-2032- Product Image
Hemophilia AAV Gene Therapy Market - Global Forecast 2026-2032- Product Image
Sale

Hemophilia AAV Gene Therapy Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6140982
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hemophilia AAV Gene Therapy Market is projected to reach USD 5.31 Billion in 2026. It is expected to continue growing at a CAGR of 23.65%, reaching USD 19.12 Billion by 2032.

Hemophilia AAV Gene Therapy: Executive Overview

Hemophilia A gene therapy uses adeno-associated virus (AAV) vectors to deliver a functional factor VIII gene to liver cells, with the aim of enabling sustained endogenous factor VIII production. The field has moved from experimental development toward regulated clinical use, while remaining focused on patient selection, durability, safety, and long-term monitoring. Key considerations include pre-existing AAV antibodies, liver health, immune responses, eligibility criteria, manufacturing consistency, and access to specialist treatment centers.

From Factor Replacement to One-Time Gene Transfer

The treatment landscape is shifting from repeated factor VIII replacement toward potentially durable gene transfer for selected adults with hemophilia A. This transition does not eliminate the need for comprehensive care: breakthrough bleeding, declining expression, inhibitor management, rehabilitation, and routine hematology follow-up remain important. Adoption is also shaped by infusion-center capacity, diagnostic standardization, payer evidence requirements, and the ability to maintain registries for long-term outcomes.

Artificial Intelligence Strengthens Selection, Monitoring, and Development

Artificial intelligence can support the field by integrating bleeding histories, factor consumption, laboratory results, liver assessments, vector-antibody testing, and longitudinal safety records. Applications include identifying patients suitable for evaluation, detecting possible immune-mediated liver injury, optimizing trial recruitment, and improving manufacturing-process analytics. These tools should remain decision-support systems, because small datasets, inconsistent clinical documentation, privacy obligations, and the need for explainable medical decisions can limit reliability.

Regional Insights Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America has strong hemophilia infrastructure, specialist centers, and experience with advanced therapies, but access depends on reimbursement, eligibility, and long-term follow-up capacity. Europe benefits from established treatment networks and coordinated clinical guidance, although national assessment and funding pathways differ. Asia-Pacific combines sophisticated centers in some economies with substantial unmet needs elsewhere, making diagnostic reach and workforce development central priorities. Latin America continues to face uneven access to factor replacement, testing, and specialist services. The Middle East has concentrated centers of excellence alongside differences in referral and financing systems, while Africa remains focused on expanding diagnosis, factor availability, registries, and specialist care before broader gene-therapy deployment can be sustained.

Group Insights: Policy Blocs and Care-System Readiness

The European Union can leverage shared scientific and regulatory collaboration while addressing variation in national reimbursement and follow-up systems. G7 countries generally possess advanced research, diagnostics, and specialist capacity, but must manage evidence standards and affordability. BRICS members show diverse readiness, ranging from established research and treatment capabilities to major gaps in diagnosis and access. ASEAN priorities include regional referral networks, laboratory capacity, and harmonized training. GCC health systems may benefit from centralized specialist programs and investment in advanced-care infrastructure. NATO members have an opportunity to strengthen cross-border preparedness, clinical cooperation, and continuity of care, while recognizing that alliance membership does not create uniform health-policy or reimbursement rules.

Country Insights: Diverse Readiness Across Fifteen Health Systems

The United States and Canada have sophisticated hemophilia centers and regulatory experience, with access shaped by coverage and specialized follow-up. The United Kingdom, France, Germany, Italy, and Spain have established European treatment networks, while national commissioning, assessment, and monitoring arrangements differ. Australia has advanced specialist services but must address geographic dispersion. Japan and South Korea combine strong clinical capabilities with country-specific regulatory and reimbursement processes. China and India have large patient populations and expanding specialist capacity, alongside continuing variation in diagnosis and access. Brazil and Mexico have important public-sector treatment programs but face regional disparities. Russia’s access and clinical pathways are shaped by national health-system conditions and supply considerations.

Priorities for Leaders: Build Evidence, Infrastructure, and Patient Trust

Industry leaders should prioritize durable evidence through prospective registries, standardized bleeding and factor-expression endpoints, and transparent long-term safety reporting. Investment should focus on reliable vector manufacturing, validated potency assays, scalable quality systems, and supply continuity. Care pathways should include pre-treatment liver assessment, antibody testing, immune-management protocols, and structured follow-up. Partnerships with hemophilia centers, patient organizations, regulators, and payers can improve informed consent and outcome-based access. Leaders should also develop equitable referral models, clinician training, data-governance safeguards, and AI tools that are clinically validated, auditable, and used with specialist oversight.

Research Methodology: Evidence Triangulation for a Specialized Therapy Field

This executive summary is based on established clinical and health-system principles relevant to AAV-mediated hemophilia A gene therapy, including regulatory concepts, treatment-center requirements, patient-selection factors, safety monitoring, and regional care-system variation. Interpretation should be grounded in peer-reviewed clinical studies, regulatory documents, clinical guidelines, treatment registries, health-technology assessments, and publicly documented policy materials. Regional, group, and country observations are qualitative and should be validated against current local evidence, because eligibility rules, reimbursement decisions, product availability, and clinical practice can change over time.

Conclusion: Durable Progress Depends on Responsible Implementation

AAV gene therapy has introduced a potentially transformative option for appropriately selected people with hemophilia A, but its value depends on more than vector administration. Durable outcomes require rigorous patient selection, specialist infrastructure, long-term surveillance, transparent evidence, and equitable financing. Regional and national differences will shape implementation, while responsible use of artificial intelligence may improve research and care without replacing clinical judgment. The strongest pathway forward combines scientific innovation with patient-centered governance and sustained health-system readiness.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hemophilia AAV Gene Therapy Market, by Vector Serotype
7.1. Introduction
7.2. AAV5
7.3. AAV8
8. Hemophilia AAV Gene Therapy Market, by Patient Population
8.1. Introduction
8.2. Adult
8.2.1. Middle Aged
8.2.2. Seniors
8.2.3. Young Adults
8.3. Pediatric
8.3.1. Adolescents
8.3.2. Children
9. Hemophilia AAV Gene Therapy Market, by Severity
9.1. Introduction
9.2. Mild
9.3. Moderate
9.3.1. On Demand Moderate
9.3.2. Prophylactic Moderate
9.4. Severe
9.4.1. On Demand Severe
9.4.2. Prophylactic Severe
10. Hemophilia AAV Gene Therapy Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. Community Hospitals
10.2.2. Teaching Hospitals
10.3. Specialty Clinics
10.3.1. Hemophilia Treatment Centers
10.3.2. Research Institutes
11. Hemophilia AAV Gene Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. Hemophilia AAV Gene Therapy Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Hemophilia AAV Gene Therapy Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Hemophilia AAV Gene Therapy Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Adverum Biotechnologies Inc.
16.2. Applied StemCell Therapeutics
16.3. Bayer AG
16.4. BioMarin Pharmaceutical Inc.
16.5. Catalent Inc.
16.6. CSL Behring
16.7. Expression Therapeutics
16.8. Freeline Therapeutics Ltd.
16.9. Pfizer Inc.
16.10. Roche Holding AG
16.11. Sangamo Therapeutics Inc.
16.12. Spark Therapeutics Inc.
16.13. Takeda Pharmaceutical Company Limited
16.14. Ultragenyx Pharmaceutical Inc.
16.15. uniQure N.V.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Hemophilia AAV Gene Therapy Market, Years Considered for the Study
FIGURE 2. Global Hemophilia AAV Gene Therapy Market, Research Design
FIGURE 3. Global Hemophilia AAV Gene Therapy Market, Research Framework
FIGURE 4. Global Hemophilia AAV Gene Therapy Market, Data Triangulation
FIGURE 5. Global Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2025 vs 2032 (%)
FIGURE 7. Global Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2025 vs 2032 (%)
FIGURE 9. Global Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Hemophilia AAV Gene Therapy Market Size, by Severity, 2025 vs 2032 (%)
FIGURE 11. Global Hemophilia AAV Gene Therapy Market Size, by Severity, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Hemophilia AAV Gene Therapy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Hemophilia AAV Gene Therapy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Hemophilia AAV Gene Therapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Hemophilia AAV Gene Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Hemophilia AAV Gene Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Hemophilia AAV Gene Therapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Hemophilia AAV Gene Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Hemophilia AAV Gene Therapy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Hemophilia AAV Gene Therapy Market Segmentation & Coverage
TABLE 2. Global Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 4. Global AAV5 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global AAV5 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global AAV5 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 11. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Middle Aged Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Middle Aged Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Middle Aged Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Seniors Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Seniors Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Seniors Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Young Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Young Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Young Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Adolescents Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Adolescents Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Adolescents Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Children Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Children Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Children Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 33. Global Mild Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Mild Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Mild Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global On Demand Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global On Demand Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global On Demand Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Prophylactic Moderate Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Prophylactic Moderate Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Prophylactic Moderate Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global On Demand Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global On Demand Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global On Demand Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Prophylactic Severe Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Prophylactic Severe Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Prophylactic Severe Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Community Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Community Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Community Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Teaching Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Teaching Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Teaching Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Hemophilia Treatment Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Hemophilia Treatment Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Hemophilia Treatment Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. North America Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. North America Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 95. North America Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 96. North America Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 97. North America Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 98. North America Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 99. North America Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 100. North America Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 101. North America Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. North America Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 103. North America Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 104. North America Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. Latin America Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Latin America Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 107. Latin America Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 108. Latin America Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 109. Latin America Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 110. Latin America Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 111. Latin America Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 112. Latin America Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 113. Latin America Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Latin America Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 115. Latin America Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 116. Latin America Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Europe Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Europe Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 119. Europe Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 120. Europe Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 121. Europe Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 122. Europe Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 123. Europe Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 124. Europe Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 125. Europe Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. Europe Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 127. Europe Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 128. Europe Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. Middle East Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Middle East Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 131. Middle East Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 132. Middle East Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 133. Middle East Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 134. Middle East Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 135. Middle East Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 136. Middle East Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 137. Middle East Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Middle East Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 139. Middle East Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 140. Middle East Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Africa Hemophilia AAV Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Africa Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 143. Africa Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 144. Africa Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 145. Africa Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 146. Africa Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 147. Africa Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 148. Africa Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 149. Africa Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Africa Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 151. Africa Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 152. Africa Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Global Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. ASEAN Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. ASEAN Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 156. ASEAN Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 157. ASEAN Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 158. ASEAN Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 159. ASEAN Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 160. ASEAN Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 161. ASEAN Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 162. ASEAN Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. ASEAN Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 164. ASEAN Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 165. ASEAN Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. GCC Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. GCC Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 168. GCC Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 169. GCC Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 170. GCC Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 171. GCC Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 172. GCC Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 173. GCC Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 174. GCC Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. GCC Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 176. GCC Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 177. GCC Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. European Union Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. European Union Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 180. European Union Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 181. European Union Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 182. European Union Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 183. European Union Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 184. European Union Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 185. European Union Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 186. European Union Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. European Union Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 188. European Union Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 189. European Union Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. BRICS Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. BRICS Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 192. BRICS Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 193. BRICS Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 194. BRICS Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 195. BRICS Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 196. BRICS Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 197. BRICS Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 198. BRICS Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. BRICS Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 200. BRICS Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 201. BRICS Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. G7 Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 203. G7 Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 204. G7 Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 205. G7 Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 206. G7 Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 207. G7 Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 208. G7 Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 209. G7 Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 210. G7 Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. G7 Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 212. G7 Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 213. G7 Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. NATO Hemophilia AAV Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. NATO Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 216. NATO Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 217. NATO Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 218. NATO Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 219. NATO Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 220. NATO Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 221. NATO Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 222. NATO Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. NATO Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 224. NATO Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 225. NATO Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Global Hemophilia AAV Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 227. United States Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 228. United States Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 229. United States Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 230. United States Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 231. United States Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 232. United States Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 233. United States Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 234. United States Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 235. United States Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. United States Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 237. United States Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 238. United States Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Canada Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 240. Canada Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 241. Canada Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 242. Canada Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 243. Canada Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 244. Canada Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 245. Canada Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 246. Canada Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 247. Canada Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Canada Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 249. Canada Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 250. Canada Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. Mexico Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 252. Mexico Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 253. Mexico Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 254. Mexico Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 255. Mexico Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 256. Mexico Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 257. Mexico Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 258. Mexico Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 259. Mexico Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. Mexico Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 261. Mexico Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 262. Mexico Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Brazil Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 264. Brazil Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 265. Brazil Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 266. Brazil Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 267. Brazil Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 268. Brazil Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 269. Brazil Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 270. Brazil Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 271. Brazil Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Brazil Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 273. Brazil Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 274. Brazil Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. United Kingdom Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 276. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 277. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 278. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 279. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 280. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 281. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 282. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 283. United Kingdom Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 285. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 286. United Kingdom Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 287. Germany Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 288. Germany Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 289. Germany Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 290. Germany Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 291. Germany Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 292. Germany Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 293. Germany Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 294. Germany Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 295. Germany Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. Germany Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 297. Germany Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 298. Germany Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. France Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 300. France Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 301. France Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 302. France Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 303. France Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 304. France Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 305. France Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 306. France Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 307. France Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. France Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 309. France Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 310. France Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. Russia Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 312. Russia Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 313. Russia Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 314. Russia Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 315. Russia Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 316. Russia Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 317. Russia Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 318. Russia Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 319. Russia Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. Russia Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 321. Russia Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 322. Russia Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 323. Italy Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 324. Italy Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 325. Italy Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 326. Italy Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 327. Italy Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 328. Italy Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 329. Italy Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 330. Italy Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 331. Italy Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 332. Italy Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 333. Italy Hemophilia AAV Gene Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 334. Italy Hemophilia AAV Gene Therapy Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. Spain Hemophilia AAV Gene Therapy Market Size, 2017-2032 (USD Million)
TABLE 336. Spain Hemophilia AAV Gene Therapy Market Size, by Vector Serotype, 2017-2032 (USD Million)
TABLE 337. Spain Hemophilia AAV Gene Therapy Market Size, by Patient Population, 2017-2032 (USD Million)
TABLE 338. Spain Hemophilia AAV Gene Therapy Market Size, by Adult, 2017-2032 (USD Million)
TABLE 339. Spain Hemophilia AAV Gene Therapy Market Size, by Pediatric, 2017-2032 (USD Million)
TABLE 340. Spain Hemophilia AAV Gene Therapy Market Size, by Severity, 2017-2032 (USD Million)
TABLE 341. Spain Hemophilia AAV Gene Therapy Market Size, by Moderate, 2017-2032 (USD Million)
TABLE 342. Spain Hemophilia AAV Gene Therapy Market Size, by Severe, 2017-2032 (USD Million)
TABLE 343. Spain Hemophilia AAV Gene Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 344. Spain Hemophilia AAV Gene Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 345. Spain Hemophilia AAV Gene Therapy Market Size, by Spec

Companies Mentioned

  • Adverum Biotechnologies Inc.
  • Applied StemCell Therapeutics
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Catalent Inc.
  • CSL Behring
  • Expression Therapeutics
  • Freeline Therapeutics Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sangamo Therapeutics Inc.
  • Spark Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • uniQure N.V.

Related Topics

Related Reports

AAV Gene Therapy Drugs Market - Global Forecast 2026-2032 - Product Image

AAV Gene Therapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
AAV Gene Therapy Injection Market - Global Forecast 2026-2032 - Product Image

AAV Gene Therapy Injection Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Hemophilia B Gene Therapy Market Report 2026 - Product Image

Hemophilia B Gene Therapy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gene Therapy - Competitive Landscape, 2026 - Product Image

Gene Therapy - Competitive Landscape, 2026

  • Report
  • 550 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2026-2034

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.